Inducible Nitric Oxide Synthase Enhances Disease Aggressiveness in Pancreatic Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Jul 2

PMID 27367029

Citations 28

Authors

Jian Wang

Peijun He

Matthias Gaida

Shouhui Yang

Aaron J Schetter

Jochen Gaedcke

B Michael Ghadimi

Thomas Ried

Harris Yfantis

Dong Lee

Jonathan M Weiss

Jimmy Stauffer

Nader Hanna

H Richard Alexander

S Perwez Hussain

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is one of the most lethal malignancies and is refractory to the available treatments. Pancreatic ductal adenocarcinoma (PDAC) expresses high level of inducible nitric oxide synthase (NOS2), which causes sustained production of nitric oxide (NO). We tested the hypothesis that an aberrantly increased NO-release enhances the development and progression of PDAC. Enhanced NOS2 expression in tumors significantly associated with poor survival in PDAC patients (N = 107) with validation in independent cohorts. We then genetically targeted NOS2 in an autochthonous mouse model of PDAC to examine the effect of NOS2-deficiency on disease progression and survival. Genetic ablation of NOS2 significantly prolonged survival and reduced tumor severity in LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mice. Primary tumor cells isolated from NOS2-deficient KPC (NKPC) mice showed decreased proliferation and invasiveness as compared to those from KPC mice. Furthermore, NKPC tumors showed reduced expression of pERK, a diminished inactivation of Forkhead box transcription factor O (FOXO3), a tumor suppressor, and a decrease in the expression of oncomir-21, when compared with tumors in KPC mice. Taken together, these findings showed that NOS2 is a predictor of prognosis in early stage, resected PDAC patients, and provide proof-of-principle that targeting NOS2 may have potential therapeutic value in this lethal malignancy.

Citing Articles

Imaging Techniques and Biochemical Biomarkers: New Insights into Diagnosis of Pancreatic Cancer.

Jafari S, Lajevardi Z, Zamani Fard M, Jafari A, Naghavi S, Ravaei F Cell Biochem Biophys. 2024; 82(4):3123-3144.

PMID: 39026059 DOI: 10.1007/s12013-024-01437-z.

The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.

ONeill C, Sun K, Sundararaman S, Chang J, Glynn S Front Physiol. 2024; 15:1358850.

PMID: 38601214 PMC: 11004480. DOI: 10.3389/fphys.2024.1358850.

Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review.

Perazzoli G, Garcia-Valdeavero O, Pena M, Prados J, Melguizo C, Jimenez-Luna C Metabolites. 2023; 13(7).

PMID: 37512579 PMC: 10384620. DOI: 10.3390/metabo13070872.

Investigation of artificial intelligence integrated fluorescence endoscopy image analysis with indocyanine green for interpretation of precancerous lesions in colon cancer.

Kim J, Kim H, Yoon Y, Kim C, Hong S, Kim S PLoS One. 2023; 18(5):e0286189.

PMID: 37228164 PMC: 10212120. DOI: 10.1371/journal.pone.0286189.

Chronic Exposure to Nitric Oxide Induces P53 Mutations and Malignant-like Features in Human Breast Epithelial Cells.

Cheng R, Burkett S, Ambs S, Moody T, Wink D, Ridnour L Biomolecules. 2023; 13(2).

PMID: 36830680 PMC: 9953427. DOI: 10.3390/biom13020311.

References

Okayama H, Saito M, Oue N, Weiss J, Stauffer J, Takenoshita S . NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Int J Cancer. 2012; 132(1):9-18. PMC: 3473150. DOI: 10.1002/ijc.27644. View

Weiss J, Back T, Scarzello A, Subleski J, Hall V, Stauffer J . Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A. 2009; 106(46):19455-60. PMC: 2773732. DOI: 10.1073/pnas.0909474106. View

Hou Y, Chao Y, Tung H, Wang H, Shan Y . Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma. Cancer. 2014; 120(17):2766-77. PMC: 4232049. DOI: 10.1002/cncr.28774. View

Song W, Wang L, Wang L, Li Q . Interplay of miR-21 and FoxO1 modulates growth of pancreatic ductal adenocarcinoma. Tumour Biol. 2015; 36(6):4741-5. DOI: 10.1007/s13277-015-3123-x. View

Pena C, Nakada Y, Saatcioglu H, Aloisio G, Cuevas I, Zhang S . LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest. 2015; 125(11):4063-76. PMC: 4639978. DOI: 10.1172/JCI82152. View

Sugita H, Kaneki M, Furuhashi S, Hirota M, Takamori H, Baba H . Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein. Mol Cancer Res. 2010; 8(8):1152-63. DOI: 10.1158/1541-7786.MCR-09-0472. View

Clark C, Hingorani S, Mick R, Combs C, Tuveson D, Vonderheide R . Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67(19):9518-27. DOI: 10.1158/0008-5472.CAN-07-0175. View

Li A, Morton J, Ma Y, Karim S, Zhou Y, Faller W . Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology. 2014; 146(5):1386-96.e1-17. PMC: 4000441. DOI: 10.1053/j.gastro.2014.01.046. View

Prueitt R, Boersma B, Howe T, Goodman J, Thomas D, Ying L . Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer. 2006; 120(4):796-805. DOI: 10.1002/ijc.22336. View

10.

Gukovsky I, Li N, Todoric J, Gukovskaya A, Karin M . Inflammation, autophagy, and obesity: common features in the pathogenesis of pancreatitis and pancreatic cancer. Gastroenterology. 2013; 144(6):1199-209.e4. PMC: 3786712. DOI: 10.1053/j.gastro.2013.02.007. View

11.

Roy S, Srivastava R, Shankar S . Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 2010; 5:10. PMC: 2915986. DOI: 10.1186/1750-2187-5-10. View

12.

Collisson E, Sadanandam A, Olson P, Gibb W, Truitt M, Gu S . Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011; 17(4):500-3. PMC: 3755490. DOI: 10.1038/nm.2344. View

13.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

14.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P . Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer. 2012; 132(4):785-94. PMC: 3488363. DOI: 10.1002/ijc.27736. View

15.

Tamir S, Tannenbaum S . The role of nitric oxide (NO.) in the carcinogenic process. Biochim Biophys Acta. 1996; 1288(2):F31-6. DOI: 10.1016/0304-419x(96)00021-2. View

16.

Lampson B, Kendall S, Ancrile B, Morrison M, Shealy M, Barrientos K . Targeting eNOS in pancreatic cancer. Cancer Res. 2012; 72(17):4472-82. PMC: 3749841. DOI: 10.1158/0008-5472.CAN-12-0057. View

17.

Lim K, Ancrile B, Kashatus D, Counter C . Tumour maintenance is mediated by eNOS. Nature. 2008; 452(7187):646-9. PMC: 2688829. DOI: 10.1038/nature06778. View

18.

Tamir S, Gal A, Weller A, Li X, Fox J, Wogan G . Nitric oxide production in relation to spontaneous B-cell lymphoma and myositis in SJL mice. Cancer Res. 1995; 55(19):4391-7. View

19.

Thomas D, Espey M, Ridnour L, Hofseth L, Mancardi D, Harris C . Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A. 2004; 101(24):8894-9. PMC: 428443. DOI: 10.1073/pnas.0400453101. View

20.

Arden K . Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol. 2006; 41(8):709-17. DOI: 10.1016/j.exger.2006.05.015. View